CORESTEMCHEMON Inc.
Research CORESTEMCHEMON Inc. (166480.KQ) on Bullrun: market cap KRW 93.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker166480.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 93.74B
- Financial periodQ2 2026
- RevenueKRW 5.40B
- Net income-KRW 3.68B
- Free cash flow-KRW 373.60M
- Gross margin-2.5%
Valuation Snapshot
latest market cap is KRW 93.74B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 93.74B | n/a | n/a | n/a |
Dividend history
About CORESTEMCHEMON Inc.
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CORESTEMCHEMON Inc.'s market cap?
CORESTEMCHEMON Inc.'s market capitalization is KRW 93.74B.
What does CORESTEMCHEMON Inc. do?
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.